ArticleInvestigational new drugs2018

Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer.

Shumei Kato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.